FR2727689B1 - - Google Patents

Info

Publication number
FR2727689B1
FR2727689B1 FR9414470A FR9414470A FR2727689B1 FR 2727689 B1 FR2727689 B1 FR 2727689B1 FR 9414470 A FR9414470 A FR 9414470A FR 9414470 A FR9414470 A FR 9414470A FR 2727689 B1 FR2727689 B1 FR 2727689B1
Authority
FR
France
Prior art keywords
vector
particle
preparing
methods
recombinant viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9414470A
Other languages
English (en)
French (fr)
Other versions
FR2727689A1 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2727689(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority to FR9414470A priority Critical patent/FR2727689A1/fr
Priority to PCT/FR1995/001590 priority patent/WO1996017070A1/fr
Priority to DK95941755T priority patent/DK0742834T4/da
Priority to CA002182303A priority patent/CA2182303C/fr
Priority to ES95941755T priority patent/ES2150595T5/es
Priority to US08/682,794 priority patent/US6110735A/en
Priority to AU43068/96A priority patent/AU707208B2/en
Priority to DE69518910A priority patent/DE69518910D1/de
Priority to DE69518910T priority patent/DE69518910T3/de
Priority to AT95941755T priority patent/ATE196507T1/de
Priority to JP51834696A priority patent/JP3989541B2/ja
Priority to PT95941755T priority patent/PT742834E/pt
Priority to EP95941755A priority patent/EP0742834B9/fr
Publication of FR2727689A1 publication Critical patent/FR2727689A1/fr
Publication of FR2727689B1 publication Critical patent/FR2727689B1/fr
Application granted granted Critical
Priority to US09/467,952 priority patent/US6281000B1/en
Priority to GR20000402737T priority patent/GR3035050T3/el
Priority to US09/938,491 priority patent/US7067310B2/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9414470A 1994-12-01 1994-12-01 Nouveau procede de preparation d'un vecteur viral Granted FR2727689A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR9414470A FR2727689A1 (fr) 1994-12-01 1994-12-01 Nouveau procede de preparation d'un vecteur viral
DE69518910T DE69518910T3 (de) 1994-12-01 1995-12-01 Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
JP51834696A JP3989541B2 (ja) 1994-12-01 1995-12-01 分子間相同組換えによるウイルスベクターの作製方法
CA002182303A CA2182303C (fr) 1994-12-01 1995-12-01 Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
ES95941755T ES2150595T5 (es) 1994-12-01 1995-12-01 Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
US08/682,794 US6110735A (en) 1994-12-01 1995-12-01 Method for the preparation of a viral vector by intermolecular homologous recombination
AU43068/96A AU707208B2 (en) 1994-12-01 1995-12-01 Method for the preparation of a viral vector by intermolecular homologous recombination
DE69518910A DE69518910D1 (de) 1994-12-01 1995-12-01 Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
PCT/FR1995/001590 WO1996017070A1 (fr) 1994-12-01 1995-12-01 Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
AT95941755T ATE196507T1 (de) 1994-12-01 1995-12-01 Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DK95941755T DK0742834T4 (da) 1994-12-01 1995-12-01 Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle
PT95941755T PT742834E (pt) 1994-12-01 1995-12-01 Processo de preparacao de um vector viral de, pelo menos 20 kb por recombinacao homologa intermolecular numa celula procariota
EP95941755A EP0742834B9 (fr) 1994-12-01 1995-12-01 Procede de preparation d'un vecteur viral d'au moins 20kb par recombinaison homologue intermoleculaire dans une cellule procaryote
US09/467,952 US6281000B1 (en) 1994-12-01 1999-12-21 Method for the preparation of a viral vector by intermolecular homologous recombination
GR20000402737T GR3035050T3 (en) 1994-12-01 2000-12-12 Method of preparing a viral vector by homologous intermolecular recombination
US09/938,491 US7067310B2 (en) 1994-12-01 2001-08-27 Method for the preparation of a viral vector by inter-molecular homologous recombination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9414470A FR2727689A1 (fr) 1994-12-01 1994-12-01 Nouveau procede de preparation d'un vecteur viral

Publications (2)

Publication Number Publication Date
FR2727689A1 FR2727689A1 (fr) 1996-06-07
FR2727689B1 true FR2727689B1 (https=) 1997-02-28

Family

ID=9469390

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9414470A Granted FR2727689A1 (fr) 1994-12-01 1994-12-01 Nouveau procede de preparation d'un vecteur viral

Country Status (13)

Country Link
US (3) US6110735A (https=)
EP (1) EP0742834B9 (https=)
JP (1) JP3989541B2 (https=)
AT (1) ATE196507T1 (https=)
AU (1) AU707208B2 (https=)
CA (1) CA2182303C (https=)
DE (2) DE69518910D1 (https=)
DK (1) DK0742834T4 (https=)
ES (1) ES2150595T5 (https=)
FR (1) FR2727689A1 (https=)
GR (1) GR3035050T3 (https=)
PT (1) PT742834E (https=)
WO (1) WO1996017070A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US6720140B1 (en) * 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
EP0996735B1 (en) * 1997-06-09 2003-12-10 Genvec, Inc. Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
JP2001517455A (ja) 1997-09-23 2001-10-09 ジェンベク、インコーポレイティッド 真核生物ウイルスベクター構築用プラスミド
CN101125873A (zh) * 1997-10-24 2008-02-20 茵维特罗根公司 利用具重组位点的核酸进行重组克隆
EP1025217B1 (en) * 1997-10-24 2006-10-04 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
EP1173460B1 (en) * 1999-03-02 2009-09-16 Life Technologies Corporation Compositions and methods for use in recombinational cloning of nucleic acids
CA2394099A1 (en) * 1999-12-07 2001-06-14 Genethon Iii Adenovirus vectors for the transfer of genes in targeted cells
NZ539430A (en) * 1999-12-10 2006-09-29 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
DK1311661T3 (da) 2000-08-14 2012-11-26 Us Gov Health & Human Serv Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
GB0027501D0 (en) * 2000-11-10 2000-12-27 Astrazeneca Ab Vector
JP2004513638A (ja) * 2000-11-10 2004-05-13 アストラゼネカ・アクチエボラーグ ベクター
WO2003052086A1 (en) * 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immune related neuronal receptors and therapeutic uses thereof
US7521242B2 (en) * 2003-05-09 2009-04-21 The United States Of America As Represented By The Department Of Health And Human Services Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids
US7960148B2 (en) * 2003-07-02 2011-06-14 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
JP4672659B2 (ja) 2003-07-21 2011-04-20 トランジェーヌ、ソシエテ、アノニム 改善されたシトシンデアミナーゼ活性を有するポリペプチド
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US7674621B2 (en) 2004-05-21 2010-03-09 The United States Of America As Represented By The Department Of Health And Human Services Plasmids and phages for homologous recombination and methods of use
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2387414A1 (en) 2009-01-13 2011-11-23 Transgene SA Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US20110015256A1 (en) * 2009-07-16 2011-01-20 Ihab Mamdouh Ishak Sadek Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP4523756A3 (en) 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
CA3036310A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
MX2019003161A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4508071A1 (en) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5582362A (en) * 1995-03-31 1996-12-10 Johnson; John R. Center feed toilet paper dispenser

Also Published As

Publication number Publication date
JP3989541B2 (ja) 2007-10-10
US6281000B1 (en) 2001-08-28
DE69518910T4 (de) 2006-02-09
GR3035050T3 (en) 2001-03-30
DK0742834T3 (da) 2001-01-29
US20020090715A1 (en) 2002-07-11
CA2182303A1 (fr) 1996-06-06
ES2150595T5 (es) 2005-12-01
DK0742834T4 (da) 2005-08-22
US6110735A (en) 2000-08-29
DE69518910T3 (de) 2006-07-13
PT742834E (pt) 2001-03-30
US7067310B2 (en) 2006-06-27
WO1996017070A1 (fr) 1996-06-06
ATE196507T1 (de) 2000-10-15
AU707208B2 (en) 1999-07-08
AU4306896A (en) 1996-06-19
CA2182303C (fr) 2005-06-21
FR2727689A1 (fr) 1996-06-07
JPH09509330A (ja) 1997-09-22
DE69518910D1 (de) 2000-10-26
EP0742834A1 (fr) 1996-11-20
DE69518910T2 (de) 2001-03-29
ES2150595T3 (es) 2000-12-01
EP0742834B2 (fr) 2005-08-03
EP0742834B1 (fr) 2000-09-20
EP0742834B9 (fr) 2005-12-28

Similar Documents

Publication Publication Date Title
FR2727689B1 (https=)
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
CZ63995A3 (en) Virus vectors and their use in gene therapy
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
GB2335194A (en) Notch
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
ZA943358B (en) Viral vectors and their use in gene therapy
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
IL110045A0 (en) Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides
GB2335426B (en) EHV-1 Vectors
IL87391A0 (en) Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
DK1124577T3 (da) Anvendelse af et enterobakterielt OmpA-protein til specifik måling til antigenpræsenterende celler
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EP0452894A3 (en) Human cells for the high expression of genes inserted in episomal recombinant dna, their preparation and their use
MY128929A (en) Vaccine against hepatitis a and hepatitis b
GEP20012489B (en) Use of Natural Human α-Interferon
ZA946008B (en) Novel tripeptides useful in immune and cns therapy
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung

Legal Events

Date Code Title Description
ST Notification of lapse